American AI drug discovery startup from San Francisco, founded 2024 by Joshua Meier (formerly Meta AI/FAIR, co-author of the ESM protein LM family). Building foundation models for biochemistry (Chai-1/2/3). Clients: Eli Lilly, Pfizer, Novartis. Series C $400M @ $3.8B valuation (July 2026).